NO20025116L - Medisinske preparater som fremmer avföring - Google Patents

Medisinske preparater som fremmer avföring

Info

Publication number
NO20025116L
NO20025116L NO20025116A NO20025116A NO20025116L NO 20025116 L NO20025116 L NO 20025116L NO 20025116 A NO20025116 A NO 20025116A NO 20025116 A NO20025116 A NO 20025116A NO 20025116 L NO20025116 L NO 20025116L
Authority
NO
Norway
Prior art keywords
adenosine
defecation
receptor antagonists
medical preparations
feces
Prior art date
Application number
NO20025116A
Other languages
English (en)
Other versions
NO20025116D0 (no
Inventor
Masahiro Yasuda
Hitoshi Harada
Shuhei Miyazawa
Seiichi Kobayashi
Kokichi Harada
Takayuki Hida
Hisashi Shibata
Nobuyuki Yasuda
Osamu Asano
Yoshihiko Kotake
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of NO20025116D0 publication Critical patent/NO20025116D0/no
Publication of NO20025116L publication Critical patent/NO20025116L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B10/00—Transmission systems employing electromagnetic waves other than radio-waves, e.g. infrared, visible or ultraviolet light, or employing corpuscular radiation, e.g. quantum communication
    • H04B10/11—Arrangements specific to free-space transmission, i.e. transmission through air or vacuum
    • H04B10/112—Line-of-sight transmission over an extended range

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Electromagnetism (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20025116A 2000-04-26 2002-10-24 Medisinske preparater som fremmer avföring NO20025116L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000126489 2000-04-26
JP2000220124 2000-07-21
PCT/JP2001/003643 WO2001080893A1 (fr) 2000-04-26 2001-04-26 Compositions medicinales favorisant les mouvements intestinaux

Publications (2)

Publication Number Publication Date
NO20025116D0 NO20025116D0 (no) 2002-10-24
NO20025116L true NO20025116L (no) 2002-12-23

Family

ID=26590887

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025116A NO20025116L (no) 2000-04-26 2002-10-24 Medisinske preparater som fremmer avföring

Country Status (16)

Country Link
US (3) US7189717B2 (no)
EP (2) EP1510222A3 (no)
JP (1) JP4128360B2 (no)
KR (2) KR100782091B1 (no)
CN (1) CN1197621C (no)
AT (1) ATE284712T1 (no)
AU (2) AU5260601A (no)
CA (1) CA2407013A1 (no)
DE (1) DE60107835T2 (no)
HU (1) HUP0300927A2 (no)
IL (2) IL152023A0 (no)
MX (1) MXPA02010552A (no)
NO (1) NO20025116L (no)
NZ (1) NZ521633A (no)
RU (2) RU2294762C2 (no)
WO (1) WO2001080893A1 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189717B2 (en) 2000-04-26 2007-03-13 Eisai Co., Ltd. Medicinal compositions promoting bowel movement
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
TWI330183B (no) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
EP2942082B1 (en) 2002-01-28 2019-03-06 Kyowa Hakko Kogyo Co., Ltd A2a receptor antogonists for use in the treatment of movement disorders
AU2003216591A1 (en) * 2002-04-10 2003-10-20 Orichid Chemicals And Pharmaceuticals Limited Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
ES2229928B1 (es) * 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
US20080058356A1 (en) * 2003-12-15 2008-03-06 Neurocrine Biosciences, Inc. 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists
SE0400233D0 (sv) * 2004-02-04 2004-02-04 Ltp Lipid Technologies Provide Rektal komposition
EP1738766A4 (en) * 2004-03-30 2010-05-12 Kyowa Hakko Kirin Co Ltd MEANS FOR THE PREVENTION AND / OR TREATMENT OF DISEASES OF CHRONIC / BONE PAIN
ES2241496B1 (es) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
EP1888565B1 (en) * 2005-04-11 2011-03-23 Almirall, S.A. 2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists
AR053712A1 (es) * 2005-04-18 2007-05-16 Neurogen Corp Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
FR2902010B1 (fr) * 2006-06-12 2008-08-22 Pierre Fabre Medicament Sa Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique
US20080009623A1 (en) * 2006-07-06 2008-01-10 Eisai R&D Management Co., Ltd. Pyrimidine compounds
US8227027B2 (en) * 2007-12-07 2012-07-24 Presspart Gmbh & Co. Kg Method for applying a polymer coating to an internal surface of a container
CN102015712A (zh) 2008-03-26 2011-04-13 阿德维纳斯治疗私人有限公司 作为腺苷受体拮抗剂的杂环化合物
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
JP5426156B2 (ja) * 2008-12-25 2014-02-26 フマキラー株式会社 排便促進用組成物
US8859566B2 (en) 2009-03-13 2014-10-14 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
JP5843778B2 (ja) 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
EP2616470B1 (en) 2010-09-13 2016-10-12 Advinus Therapeutics Limited Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
ES2552989T3 (es) 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
WO2013119895A1 (en) 2012-02-08 2013-08-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
AR090220A1 (es) 2012-03-01 2014-10-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
JP6378182B2 (ja) 2012-08-27 2018-08-22 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性│疾患の処置のためのセリン／スレオニンキナーゼ阻害剤
ES2580702B1 (es) * 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
JP2017149663A (ja) * 2016-02-24 2017-08-31 株式会社Ｌｔｔバイオファーマ 過敏性腸症候群治療剤
CN105687225B (zh) * 2016-02-26 2018-07-06 四川好医生攀西药业有限责任公司 一种治疗肠易激综合征的药物组合物及其制备方法和应用
SG11201900687VA (en) 2016-07-29 2019-02-27 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
UA125519C2 (uk) 2016-07-29 2022-04-13 Суновіон Фармасьютікалз Інк. Сполуки і композиції і їх застосування
CA3070993A1 (en) 2017-08-02 2019-02-07 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
WO2019121374A1 (en) * 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
EP3820474A4 (en) * 2018-07-10 2022-03-23 Nikang Therapeutics, Inc. ADENOSINE RECEPTOR BINDING COMPOUNDS
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
US4673680A (en) 1985-09-18 1987-06-16 Pendleton Robert G α2 -adrenergic receptor antagonists as modifiers of gastrointestinal motility
JPH06102662B2 (ja) 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
JPH04271770A (ja) 1991-02-27 1992-09-28 Asahi:Kk お茶
JP3343965B2 (ja) * 1992-10-31 2002-11-11 ソニー株式会社 音声符号化方法及び復号化方法
CN1088053A (zh) 1993-01-04 1994-06-22 谷中村 一种益寿保健茶叶
JPH06211669A (ja) 1993-01-14 1994-08-02 Kyowa Hakko Kogyo Co Ltd 腸運動の異常亢進治療剤
WO1994016702A1 (en) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for irregular bowel movement
JP3123286B2 (ja) * 1993-02-18 2001-01-09 ソニー株式会社 ディジタル信号処理装置又は方法、及び記録媒体
GB9309573D0 (en) * 1993-05-10 1993-06-23 Merck Sharp & Dohme Therapeutic agents
JP3277679B2 (ja) * 1994-04-15 2002-04-22 ソニー株式会社 高能率符号化方法と高能率符号化装置及び高能率復号化方法と高能率復号化装置
EP0888335A4 (en) * 1996-03-13 2002-01-02 Smithkline Beecham Corp NEW PYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CYTOKININ MEDIATOR DISEASES
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
CZ9902016A3 (cs) 1996-12-05 1999-11-17 Amgen Inc. Substituované pyrimidinonové a pyridonové sloučeniny a způsoby jejich použití
TW520362B (en) 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
DE69815554T2 (de) 1998-01-05 2004-05-06 Eisai Co., Ltd. Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen
JP3990061B2 (ja) 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
CA2239294A1 (en) * 1998-05-29 1999-11-29 Majid Foodeei Methods and apparatus for efficient quantization of gain parameters in glpas speech coders
BR9911612A (pt) * 1998-06-02 2001-02-06 Osi Pharm Inc Composições de pirrolo[2,3d]pirimidina e seus usos
WO1999064418A1 (en) * 1998-06-05 1999-12-16 Novartis Ag Aryl pyridinyl thiazoles
EP1090022B1 (en) * 1998-06-23 2003-08-06 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
AUPP672198A0 (en) * 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
FR2791167B1 (fr) * 1999-03-17 2003-01-10 Matra Nortel Communications Procedes de codage, de decodage et de transcodage audio
DK1221444T3 (da) 1999-07-02 2005-11-14 Eisai Co Ltd Kondenserede imidazolforbindelser og lægemidler mod diabetes mellitus
EP1136482A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
EP1136486A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Indanylamino]pyrimidone and 2-[tetrahydronaphthalenylamino]pyrimidone derivatives
WO2001070727A1 (en) 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
US7189717B2 (en) 2000-04-26 2007-03-13 Eisai Co., Ltd. Medicinal compositions promoting bowel movement

Also Published As

Publication number Publication date
US20030171383A1 (en) 2003-09-11
KR100782091B1 (ko) 2007-12-04
US20070054876A1 (en) 2007-03-08
EP1510222A3 (en) 2007-05-23
KR20070058022A (ko) 2007-06-07
ATE284712T1 (de) 2005-01-15
EP1283056A1 (en) 2003-02-12
US7189717B2 (en) 2007-03-13
RU2002131637A (ru) 2004-03-27
HUP0300927A2 (hu) 2003-07-28
DE60107835T2 (de) 2005-12-22
EP1283056B1 (en) 2004-12-15
AU5260601A (en) 2001-11-07
NZ521633A (en) 2005-01-28
JP4128360B2 (ja) 2008-07-30
WO2001080893A1 (fr) 2001-11-01
NO20025116D0 (no) 2002-10-24
MXPA02010552A (es) 2003-03-10
CN1197621C (zh) 2005-04-20
AU2001252606B2 (en) 2005-07-07
IL152023A0 (en) 2003-04-10
RU2294762C2 (ru) 2007-03-10
KR20020089495A (ko) 2002-11-29
DE60107835D1 (de) 2005-01-20
IL188052A0 (en) 2008-03-20
EP1510222A2 (en) 2005-03-02
CN1426310A (zh) 2003-06-25
CA2407013A1 (en) 2002-10-22
EP1283056A4 (en) 2003-07-02
RU2005127415A (ru) 2007-03-10
US20060270674A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
NO20025116L (no) Medisinske preparater som fremmer avföring
BR0110420A (pt) Agonistas muscarìnicos
SE9404196D0 (sv) New antithrombotic formulation
CA2408537A1 (en) Treating irritable bowel syndrome or disease
RU2210573C2 (ru) Углеводные производные
DE60023300D1 (de) Verwendung von cpg als adjuvans für hivimpstoff
DE69932510D1 (de) Vaskularisierungsinhibitoren
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
NZ294878A (en) Water soluble derivatives of epipodophyllotoxin and medicaments
DE10075036I2 (de) Impfstoff und Diagnostikum f}r den Schweine-Cholera-Virus.
BR9909971A (pt) Uso de um composto, processo para tratamento ou prevenção da sìndrome de intestinos irritáveis, e, composição farmacêutica para o tratamento da sìndrome dos intestinos irritáveis
MX9705916A (es) Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc.
KR960023048A (ko) 돼지 유행성 설사병 예방약 생산을 위한 약독화 바이러스주
王春河 et al. 120 Cases of pseudobulbar paralysis treated by needling lianquan and chize
孙仲篪 et al. ANALYSIS ON THE CURATIVE EFFECT OF QUADRICEPS PLASTY
NO964252D0 (no) Anvendelsen av spiramycin for behandling av gastrointestinale mangler som forårsaket av H.pylori
岳红文 et al. The medical value of Radix Puerariae and puerarin in treating diseases of the cardiovascular system
Lee The Beri-Beri Hospital, Singapore (1907-1925)
汤光 Pharmaceutical Care
程秋云 et al. Remission of Abdominal Colic During Enteroscopy by Injecting Vitamin K_3 into Zusanli Acupoint
钟登华 DIAGNOSTIC CHECKING FOR TIME SERIES MODELS USING NONPARAMETRIC APPROACH
徐麟鹤 et al. ELECTRON MICROSCOPIC OBSERVATIONS OF TEGUMENTAL DAMAGE IN ADULT SCHISTOSOMA JAPONICUM AFTER IN VIVO TREATMENT WITH LEVO-PRAZIQUANTEL
麻柔 Further Study of the Treatment of Acute Leukemiawith Toxic Chinese Medicine
马连生 et al. COMBINATION OF TRADITIONAL CHINESE MEDICINE AND WESTERN MEDICINE IN THE TREATMENT OF RESISTANT PEPTIC ULCER
SE9902673D0 (sv) New composition

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application